Dr. Keith Rawlings brings over 30 years of HIV clinical, research, and administrative experience to his role at ViiV Healthcare.
As Senior Medical Director, Keith provides scientific and medical expertise for ViiV initiatives including sponsored clinical trials; investigator-initiated studies; and medical education programs.
Prior to joining ViiV Healthcare, Dr. Rawlings was Director, HIV Medical Sciences at Gilead Sciences, where he oversaw education and training on HIV prevention, along with the regulatory submission, approval and implementation of Truvada® for pre-exposure prophylaxis in the U.S. He also was Medical Director, Director of Clinical Research and the AIDS Clinical Trials Group (ACTG) Site Leader and Principal Investigator for the AIDS Arms, Inc. in Dallas, Texas.
He has previously served as Chair of Internal Medicine Section and Co-Chair of the Infectious Diseases/HIV program of the National Medical Association (NMA); on the Health Resources and Services Administration (HRSA) AIDS Advisory Committee; as Co-Principal Investigator and Advisory Board member of the National Minority AIDS Education and Training Center; as a member of the Board of Directors of the American Academy of HIV Medicine; and on the South African Presidential HIV Advisory Board. He has published over 100 articles, abstracts and manuscripts and co-edited one of the few books, HIV/AIDS in U.S. Communities of Color, which addressed the HIV epidemic among minorities in the U.S.
Keith received his MD degree from the University of Maryland School of Medicine in Baltimore and completed a Residency in Internal Medicine at Union Memorial Hospital in Baltimore.